HER-2/neu targeting for recurrent vulvar Paget's disease. A case report and literature review

Amer Karam; Jonathan S. Berek; Amy Stenson; Jian Yu Rao; Oliver Dorigo

doi:10.1016/j.ygyno.2007.12.014

HER-2/neu targeting for recurrent vulvar Paget's disease. A case report and literature review

Amer Karam, Jonathan S. Berek, Amy Stenson, Jian Yu Rao, Oliver Dorigo

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Background: The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target. Case: We report the case of a 52-year-old patient with persistent Paget's disease of the vulva despite eight surgical excisions over a 15-year period. Immunohistochemistry demonstrated overexpression of the HER-2/neu protein in the vulva resection specimen. Treatment with Trastuzumab resulted in a significant regression of her disease and resolution of symptoms. Conclusion: Based on our case report, therapeutic targeting of HER-2/neu for patients with Paget's disease of the vulva using for example Trastuzumab is a potentially effective, alternative approach, and warrants further investigation.

Original language	English (US)
Pages (from-to)	568-571
Number of pages	4
Journal	Gynecologic oncology
Volume	111
Issue number	3
DOIs	https://doi.org/10.1016/j.ygyno.2007.12.014
State	Published - Dec 1 2008
Externally published	Yes

Keywords

HER-2/neu
Paget's
Targeted therapy
Vulva

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/j.ygyno.2007.12.014

Cite this

@article{7ee954810f364d38805219edb627b312,

title = "HER-2/neu targeting for recurrent vulvar Paget's disease. A case report and literature review",

abstract = "Background: The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target. Case: We report the case of a 52-year-old patient with persistent Paget's disease of the vulva despite eight surgical excisions over a 15-year period. Immunohistochemistry demonstrated overexpression of the HER-2/neu protein in the vulva resection specimen. Treatment with Trastuzumab resulted in a significant regression of her disease and resolution of symptoms. Conclusion: Based on our case report, therapeutic targeting of HER-2/neu for patients with Paget's disease of the vulva using for example Trastuzumab is a potentially effective, alternative approach, and warrants further investigation.",

keywords = "HER-2/neu, Paget's, Targeted therapy, Vulva",

author = "Amer Karam and Berek, {Jonathan S.} and Amy Stenson and Rao, {Jian Yu} and Oliver Dorigo",

year = "2008",

month = dec,

day = "1",

doi = "10.1016/j.ygyno.2007.12.014",

language = "English (US)",

volume = "111",

pages = "568--571",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - HER-2/neu targeting for recurrent vulvar Paget's disease. A case report and literature review

AU - Karam, Amer

AU - Berek, Jonathan S.

AU - Stenson, Amy

AU - Rao, Jian Yu

AU - Dorigo, Oliver

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background: The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target. Case: We report the case of a 52-year-old patient with persistent Paget's disease of the vulva despite eight surgical excisions over a 15-year period. Immunohistochemistry demonstrated overexpression of the HER-2/neu protein in the vulva resection specimen. Treatment with Trastuzumab resulted in a significant regression of her disease and resolution of symptoms. Conclusion: Based on our case report, therapeutic targeting of HER-2/neu for patients with Paget's disease of the vulva using for example Trastuzumab is a potentially effective, alternative approach, and warrants further investigation.

AB - Background: The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target. Case: We report the case of a 52-year-old patient with persistent Paget's disease of the vulva despite eight surgical excisions over a 15-year period. Immunohistochemistry demonstrated overexpression of the HER-2/neu protein in the vulva resection specimen. Treatment with Trastuzumab resulted in a significant regression of her disease and resolution of symptoms. Conclusion: Based on our case report, therapeutic targeting of HER-2/neu for patients with Paget's disease of the vulva using for example Trastuzumab is a potentially effective, alternative approach, and warrants further investigation.

KW - HER-2/neu

KW - Paget's

KW - Targeted therapy

KW - Vulva

UR - http://www.scopus.com/inward/record.url?scp=56449096798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449096798&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.12.014

DO - 10.1016/j.ygyno.2007.12.014

M3 - Article

C2 - 18252264

AN - SCOPUS:56449096798

SN - 0090-8258

VL - 111

SP - 568

EP - 571

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -

HER-2/neu targeting for recurrent vulvar Paget's disease. A case report and literature review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this